Almirall, a pharmaceutical company and CataloniaBio & HealthTech member based in Barcelona, has appointed Gianfranco Nazzi as its new CEO, taking over for Peter Guenter. He will officially join the company on 1 May. 

Nazzi has a degree in Economics and Banking from the University of Udine (Italy). He had been headhunted by Almirall from Teva Pharmaceuticals Industries Ltd, where he was executive vice-president for foreign markets and a member of the executive board. Previously, he has also held positions of responsibility at AstraZeneca, GSK and Eli Lilly.

More information

You may also be interested in:

• Almirall and Tyris Therapeutics join forces to develop gene therapies
• Almirall enters the IBEX 35
• Almirall acquires the American Bioniz Therapeutics